UNASSIGNED: Background @entity8142 agonists ( @entity6757 RA) added to insulin in type 2 @entity6 @entity1 have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate @entity6757 RA treatment on body weight, glycaemic control and total daily insulin dose in @entity28 , insulin-using type 2 @entity6 @entity1 after 2  years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible @entity1 were at least 18  years of age, were on insulin therapy and @entity28 (BMI  >  30  kg/m(2)), started @entity6757 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2  years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 @entity1 started with exenatide or liraglutide. 120 @entity1 completed the 2  years follow-up. From baseline to 2  years, body weight (mean      SD) changed from 117.9      22.1 to 107.9      22.9  kg (P  <  0.0001), HbA1c (median, IQR) changed from 7.9 (7.2-8.9) to 7.6 (6.9-8.3)  % [63 (55-74) to 60 (52-67)  mmol/mol] (P  <  0.0001), total daily insulin dose changed from 90 (56-150) to 60 (0-100)  Units/day (P  <  0.0001). Weight change differed between eating behaviour groups (P  <  0.001) in which external eating behaviour (n  =  17) resulted in the smallest decline (-3.1  %) and restrained (n  =  41) in the greatest (-10.3  %) in comparison with emotional (n  =  37, -8.5  %) and indifferent (n  =  25, -9.6  %) eating behaviours. Conclusion Two year of @entity6757 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in @entity28 , insulin-using type 2 @entity6 @entity1 in a real life setting. Largest weight loss was achieved in @entity1 with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction.

The effects of @entity6757 analogues in XXXX , insulin-using type 2 @entity6 in relation to eating behaviour.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1'] @entity8142 :: ('2740', 'Gene') :: ['Glucagon-like peptide-1 receptor']
@entity28 :: (MESH:D009765,Disease) :: ['obese']
